[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 14, 1998

BRCA1and Medullary Breast Cancer

Author Affiliations
 

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;280(14):1227-1228. doi:10.1001/jama.280.14.1227

To the Editor.—According to the American Society of Clinical Oncology recommendations,1 genetic testing for breast cancer should be performed when the a priori probability of finding a mutation is at least 10%. Based on this recommendation, recent articles in JAMA2,3 may affect BRCA1screening indications, since the observed detection mutation rates are lower than previously thought. The lowest rate can be attributed to the lack of power of the current screening methods, the low prevalence rate of BRCA1germline mutations in the populations now under study, or both.

First Page Preview View Large
First page PDF preview
First page PDF preview
×